The patent WO2003077914A1 details the synthesis of binimetinib, also known as MEK162 or ARRY-162. This compound is a selective inhibitor of MEK1 and MEK2, enzymes involved in the RAS/RAF/MEK/ERK signaling pathway [1].
How is Binimetinib Synthesized According to Patent WO2003077914A1?
The patent outlines a multi-step synthesis process for binimetinib. Key intermediates and reaction steps are described, focusing on the construction of the core chemical structure. For instance, the synthesis involves the preparation of substituted anilines and pyrimidines that are subsequently coupled to form the final molecule [1]. Specific reagents and conditions are provided for each step, enabling the formation of the active pharmaceutical ingredient.
What is the Chemical Structure of Binimetinib?
Binimetinib's chemical name is 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-N-(2-((methylsulfonyl)amino)phenyl)-1H-pyrazole-3-carboxamide [1]. Its structure is characterized by a pyrazole core substituted with various functional groups, including halogen atoms, amino linkages, and sulfonylamide moieties.
What is Binimetinib Used For?
Binimetinib is used in combination with encorafenib for the treatment of patients with BRAF V600E or V600K mutant unresectable or metastatic melanoma. It is also investigated for other cancers driven by the BRAF pathway [1].
What is the Significance of the MEK Pathway in Cancer?
The MEK pathway, specifically MEK1 and MEK2, is a crucial component of the RAS/RAF/MEK/ERK signaling cascade. Dysregulation of this pathway, often due to mutations in BRAF or RAS, can lead to uncontrolled cell growth and proliferation, contributing to cancer development and progression. Inhibiting MEK can block downstream signaling, thereby suppressing tumor growth [1].
When Might Binimetinib Patents Expire?
Patent expiration dates can be complex, involving multiple patents covering the compound itself, its synthesis, and its uses. For specific patent expiry information, including details on granted patents and potential extensions, a dedicated patent database would be necessary. DrugPatentWatch.com is a resource that provides such information [2].
What Are the Competitors to Binimetinib?
Binimetinib, often used in combination with encorafenib, faces competition from other targeted therapies for BRAF-mutated cancers. These include other MEK inhibitors and BRAF inhibitors, as well as immunotherapies, which may be used alone or in combination [1].
What is the Regulatory Status of Binimetinib?
Binimetinib has received regulatory approval in various regions, including the United States and Europe, for specific indications, primarily in combination with encorafenib for melanoma [1].
What is the Role of Clinical Data in Binimetinib's Development?
Clinical trials have been essential in establishing the efficacy and safety of binimetinib, particularly in combination regimens. These studies provide the data necessary for regulatory submissions and demonstrate the drug's benefit in specific patient populations with BRAF-mutated cancers [1].
Sources:
[1] WO2003077914A1
[2] https://drugpatentwatch.com/